Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses

Journal of Clinical Psychiatry

Volumn 70, Issue SUPPL. 3, 2009, Pages 30-36

  Newcomer, John W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Campus Box 8134 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; MESORIDAZINE; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

BIPOLAR MANIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; HEALTH CARE ACCESS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MENTAL DISEASE; MORTALITY; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION; BIPOLAR DISORDER; COMPARATIVE STUDY;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; MENTAL DISORDERS; OBESITY; SCHIZOPHRENIA;

EID: 68849123148     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.7075su1c.05     Document Type: Review

References (39)

1. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):1-14.
2. Lutterman T, Ganju V, Schach L, et al. Sixteen State Study on Mental Health Performance Measures. DHHS Publication No. (SMA) 03-3835. Rockville, Md. Center for Mental Health Services, Substance Abuse and Mental Health Services Administration. 2003. http://www.nri-inc.org/reports-pubs/2003/16StateStudy2003. pdf. Accessed Dec 4, 2008.
3. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794-1796. (Pubitemid 47598448)
4. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58(6):565-572.
5. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic side effects: a comprehensive literature review. CNS Drugs. 2005;19 (suppl 1):1-93. (Pubitemid 40677047)
6. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-455. (Pubitemid 46556468)
7. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003;28(suppl 1): 9-26. (Pubitemid 36015659)
8. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20(5):491-505.
9. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763-771.
10. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185-194. (Pubitemid 44480836)
11. Risperdal (risperidone) [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; 2007. http://www.risperdal.com/ risperdal/shared/pi/risperdal.pdf. Accessed Mar 27, 2009.
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. (Pubitemid 41345943)
13. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-2095.
14. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765-774. (Pubitemid 32429846)
15. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12):1624-1633.
16. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience With Safety and Tolerability (QUEST) study. Clin Ther. 2001;23(11): 1839-1854. (Pubitemid 33121972)
17. Lublin H, Haug HJ, Koponen H, et al. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial [E-pub ahead of print Sep 19, 2008]. World J Biol Psychiatry. doi: 10.1080/156229 70802269589.
18. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509-516. (Pubitemid 43764227)
19. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11): 1686-1696. (Pubitemid 29517559)
20. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123-136. (Pubitemid 36513927)
21. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622. (Pubitemid 44464570)
22. Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial [E-pub ahead of print Nov 20, 2008]. Schizophr Res. doi: 10.1016/j.schres.2008.10.011.
23. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-994.
24. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046-1056.
25. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? data from the CATIE trial. Schizophr Res. 2009; 107(1):22-29.
26. Stroup TC, McEvoy JP, Swartz MS, et al. Comparison of Antipsychotics for Metabolic Problems (CAMP): a NIMH Schizophrenia Trials Network Study. Clin Schizophr Rel Psychoses. 2007;1(1):69-72.
27. McElroy SL. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry. 2009;70(suppl 3):12-21.
28. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277-288. (Pubitemid 32324233)
29. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotictreated patients. Neuropsychopharmacology. 2007;32(12):2561-2569.
30. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272.
31. Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69(2):316-322.
32. US Food and Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Patient Safety News. June 2004. http://www.accessdata. fda.gov/scripts/cdrh/cfdocs/psn/ transcript.cfm?show=28#4. Accessed Dec 19, 2008.
33. Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin. 2006;22(12):2345-2353.
34. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009; 166(3):345-353.
35. Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the ADA's consensus statement on antipsychotic drugs and diabetes [E-pub ahead of print Feb 24, 2009]. Diabetes Care. 2009. doi: 10.2337/dc08-1720.
36. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation. 1998;97(18):1876-1887.
37. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97(11):1095-1102. (Pubitemid 28145381)
38. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol. 2005;99(3):1193-1204.
39. De Backer G, Ambrosioni E, Borch-Johnsen K, et al and the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;Sep;24(17): 1601-1610.